TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER
Clinical safety rating
cautionComprehensive clinical and safety monograph for TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER (TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER).
Travasol 4.25% in Dextrose 15% is a combination of amino acids and dextrose used for parenteral nutrition. Amino acids provide substrates for protein synthesis, while dextrose provides a source of calories. The mechanism involves intravenous administration bypassing the gastrointestinal tract to deliver nutrients directly into the bloodstream, supporting tissue repair, growth, and metabolic functions.
| Metabolism | The amino acids in Travasol are metabolized via various pathways including transamination, deamination, and urea cycle in the liver and other tissues. Dextrose undergoes glycolysis and oxidative phosphorylation to produce ATP. |
| Excretion | TRAVASOL 4.25% IN DEXTROSE 15% (amino acids and dextrose) is a parenteral nutrition solution. Amino acids are metabolized to urea, which is excreted renally; dextrose is metabolized to CO2 and water. No significant biliary/fecal elimination. |
| Half-life | Not applicable as a single entity; components have intrinsic half-lives. Amino acids: rapid distribution (minutes), with terminal elimination of metabolites (e.g., urea) ~4-8 hours. Dextrose: half-life ~1-2 hours in steady state. |
| Protein binding | Amino acids: minimal to no protein binding (<10%). Dextrose: not protein bound. |
| Volume of Distribution | Total body water distribution: ~0.55 L/kg for amino acids; dextrose distributes in extracellular fluid (~0.2 L/kg). |
| Bioavailability | IV: 100% bioavailability; not administered orally or via other routes. |
| Onset of Action | IV infusion: immediate onset for nitrogen balance and caloric provision; metabolic effects within minutes to hours. |
| Duration of Action | Duration of nutritional support is continuous during infusion. Post-infusion, metabolic effects persist for hours (amino acid oxidation, glucose regulation). |
| Molecular Weight | Amino acids: range 75-204 Da; Dextrose: 180.16 Da |
Intravenous infusion; typical adult dose is 500 mL to 1000 mL per day, administered at a rate of 200 mL/hour, adjusted based on metabolic and fluid needs.
| Dosage form | INJECTABLE |
| Renal impairment | In acute kidney injury or chronic kidney disease with GFR <30 mL/min, reduce volume and rate; monitor for electrolyte imbalances; consider avoidance in severe renal impairment. |
| Liver impairment | No specific Child-Pugh based adjustments; use with caution in severe hepatic encephalopathy; monitor ammonia levels. |
| Pediatric use | Dose based on weight: 2 to 6 g/kg/day of amino acids and 15 g/kg/day of dextrose; start at 2 g/kg/day of amino acids and titrate; typical infusion rate 100-200 mL/kg/day. |
| Geriatric use | Start at lower infusion rates (e.g., 100 mL/hour); monitor fluid balance, renal function, and electrolytes; reduce total volume to avoid fluid overload. |
| 1st trimester | Amino acids and dextrose are essential nutrients; no fetal risk expected when used as indicated. However, avoid unnecessary use. Cautious use only if clearly needed. |
| 2nd trimester | No known teratogenic effects; can be used for maternal nutritional support. |
| 3rd trimester | Safe for maternal nutritional support; monitor maternal glucose and electrolytes. |
Clinical note
Comprehensive clinical and safety monograph for TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER (TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER).
| Placental transfer | Amino acids and dextrose are endogenous substances; actively transferred across placenta to support fetal nutrition. |
| Breastfeeding | Excreted in breast milk as normal nutrients; no adverse effects expected. Compatible with breastfeeding. |
| Lactation Rating | L1 (Safe) |
| Teratogenic Risk | No expected increase in fetal malformation risk; amino acids and dextrose are endogenous nutrients. However, electrolyte disturbances or hyperglycemia may occur and can affect fetal development. First trimester: theoretical risk from metabolic derangements. Second and third trimesters: fetal growth and metabolic monitoring recommended. |
| Fetal Monitoring | Monitor maternal blood glucose, electrolytes, fluid balance, and renal function. Fetal monitoring includes serial growth ultrasounds and nonstress tests if maternal metabolic complications arise. |
| Fertility Effects | No specific adverse effects on fertility reported; as a nutritional supplement, it may support normal reproductive function in malnourished women. |
■ FDA Black Box Warning
None
| Serious Effects |
Severe metabolic acidosisHyperglycemia or diabetes mellitus out of controlSevere electrolyte disordersAnuria or oliguria not related to dehydrationKnown hypersensitivity to any component
| Precautions | Do not administer if solution is discolored or contains particulate matter, Use with caution in patients with renal impairment, hepatic failure, or metabolic disorders, Monitor fluid and electrolyte balance, blood glucose, and acid-base status, Risk of infections related to catheter use, Rebound hypoglycemia may occur upon abrupt discontinuation |
| Food/Dietary | No oral intake restrictions specific to this formulation as it is for parenteral use. However, if transitioning to oral feeding, coordinate with dietitian to avoid electrolyte imbalances or overfeeding. |
| Clinical Pearls | TRAVASOL 4.25% IN DEXTROSE 15% is a high-osmolarity parenteral nutrition solution (approximately 1700 mOsm/L). Must be administered via central venous line to avoid thrombophlebitis. Monitor serum glucose, electrolytes, renal function, and liver enzymes frequently. Risk of hyperglycemia, especially in stressed patients; consider insulin coverage. Do not use as a peripheral line solution due to high osmolarity. |
| Patient Advice | This solution is given through a large vein in your chest, not a small vein in your arm. · You may need regular blood tests to check your blood sugar, kidney function, and mineral levels. · Report any signs of infection at the catheter site, such as redness, swelling, or pain. · Tell your healthcare provider if you feel unusually thirsty, urinate frequently, or have blurred vision. · Do not stop the infusion suddenly without medical advice. |
Loading safety data…